Boule Diagnostics is raising 93.2 million SEK via a rights issue to fund a business restructuring that discontinues its instrument division in favor of higher-margin recurring revenue streams.
Boule Diagnostics has resolved a fully secured rights issue of approximately SEK 93.2 million at SEK 0.80 per share, with each existing share granting three new shares. The proceeds will fund the wind-down of the instrument business and the shift to consumables, service and OEM, targeting annual cost savings of SEK 90–100 million from 2028. While the dilution from the 3:1 ratio may pressure the stock short-term, the full subscription commitments and strategic focus on recurring revenue could support a recovery.
SEK 0.80 per share, with each existing share entitling the holder to subscribe for three new shares.
Approximately SEK 93.2 million before issue costs, with an over-allotment option of up to approximately SEK 63 million.
Boule Diagnostics AB has announced a fully secured rights issue of approximately 93.2 million SEK to support its strategic pivot away from instrument manufacturing. The company plans to focus exclusively on consumables, services, and its OEM business, targeting annual cost savings of 90-100 million SEK by 2028.
The proceeds will finance the wind-down of the company's instrument business and support the transition to a focus on consumables, services, and the OEM CDS business.
The meeting is expected to be held on 7 December 2026.